Federal Contractor Profile
Iit Research Institute
$56M obligated·101 awards·2 agencies·12 NAICS
Federal Contracts
Showing award actions 1–50 of 141 funded award actions, most recent first.
- Contracts with positive obligations
- 101
- Funded award actions shown
- 141
- Obligations shown
- $56M
- Awarding agencies
- 2
This table shows award actions with a positive obligation. Zero-dollar and negative-dollar actions, such as administrative changes and deobligations, are not displayed. Multiple award actions may belong to the same contract.
Award data as of September 28, 2026. Source: USAspending federal award records.
| Date | Agency | PIID | NAICS | Description | Amount |
|---|---|---|---|---|---|
| Sep 16, 2026 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH OLAO | 75N98026F00003 | 541715 | IITRI - 2026 SF IND-ENABLING GLP TOXICOLOGY STUDIES | $46K |
| Sep 11, 2026 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH OLAO | 75N98026F00002 | 541715 | IITRI - PA1 TASK ORDER #07 | $109K |
| Aug 11, 2026 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95024F00002 | 541715 | FIRST-IN-CLASS SMALL MOLECULE CANDIDATE NCGC72 (CD206 AGONIST) FOR IMMUNOLOGICALLY COLD SOLID ORGAN CANCERS | $35K |
| Jul 29, 2026 | Department of Health and Human ServicesNIH NCI | 75N91022C00010 | 541715 | PRECLINICAL TOXICOLOGY OF LARGE MOLECULE DRUGS DEVELOPED FOR CANCER AND OTHER INDICATIONS | $550K |
| Jun 30, 2026 | Department of Health and Human ServicesNIH NCI | 75N91024F00003 | 541715 | TOXICOLOGY STUDIES IN RATS AND DOGS ADMINISTERED AIT-102 | $60K |
| Jun 26, 2026 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH OLAO | 75N98026F00001 | 541715 | TASK ORDER AWARD- SSL GLP AND NON-GLP TOXICOLOGY STUDIES | $3.4M |
| Mar 27, 2026 | Department of Health and Human ServicesNIH NCI | 75N91022C00010 | 541715 | PRECLINICAL TOXICOLOGY OF LARGE MOLECULE DRUGS DEVELOPED FOR CANCER AND OTHER INDICATIONS | $10K |
| Feb 25, 2026 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95024F00001 | 541715 | IITRI - PERFORMANCE AREA 1 TO2 | $46K |
| Feb 6, 2026 | Department of Health and Human ServicesNIH NCI | 75N91026F00001 | 541715 | TOXICOLOGY STUDIES IN MICE ADMINISTERED MTX-531 - FINAL DELIVERABLES | $68K |
| Sep 25, 2025 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95025F00001 | 541715 | PTTP TASK ORDER - IITRI - MS RODENT AND NON-RODENT MTD-DRF STUDIES | $401K |
| Mar 19, 2025 | Department of Health and Human ServicesNIH NCI | 75N91024F00002 | 541715 | TOXICOLOGY STUDIES IN MICE AND DOGS ADMINISTERED MTX-531 | $451K |
| Mar 13, 2025 | Department of Health and Human ServicesNIH NCI | 75N91022C00010 | 541715 | PRECLINICAL TOXICOLOGY OF LARGE MOLECULE DRUGS DEVELOPED FOR CANCER AND OTHER INDICATIONS | $10K |
| Feb 25, 2025 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95024F00001 | 541715 | IITRI - PERFORMANCE AREA 1 TO2 | $85K |
| Jan 16, 2025 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95020F00001 | 541712 | NON-CLINICAL SAFETY OF PTH-1A, INVERSE AGONIST, TO SUPPORT JANSEN METAPHYSEAL CHONDRODYSPLASIA (JMC) DISEASE. POP: 09/16/2020 TO 03/15/2020. | $51K |
| Nov 5, 2024 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95024F00002 | 541715 | IITRI - PTTP DRF BPN STUDY - TO3 | $218K |
| Sep 16, 2024 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95024F00002 | 541715 | FIRST-IN-CLASS SMALL MOLECULE CANDIDATE NCGC72 (CD206 AGONIST) FOR IMMUNOLOGICALLY COLD SOLID ORGAN CANCERS | $512K |
| Sep 6, 2024 | Department of Health and Human ServicesNIH NCI | 75N91024F00003 | 541715 | TOXICOLOGY STUDIES IN RATS AND DOGS ADMINISTERED AIT-102 | $568K |
| Sep 5, 2024 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95024F00003 | 541715 | IITRI -DOG MTD-DRF STUDIES-TO 4 | $14K |
| Aug 30, 2024 | Department of Health and Human ServicesNIH NCI | 75N91020F00001 | 541714 | TASK ORDER: TOPICAL RESATORVID FOR NONMELANOMA SKIN CANCER PREVENTION PERIOD OF PERFORMANCE: 09/21/2020 - 03/20/2022 | $154K |
| Jul 31, 2024 | Department of Health and Human ServicesNIH NCI | 75N91020F00001 | 541714 | PREVENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMARKERS; TASK ORDER TITLE: PRECLINICAL DEVELOPMENT OF AN RNA VACCINE FOR IMMUNOPREVENTION OF PROSTATE CANCER | $1.0M |
| Jul 23, 2024 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95024F00004 | 541715 | IITRI - NON-GLP DOSE RANGE FINDING (DRF) STUDIES-DEC. 2023 #2 | $202K |
| Jul 22, 2024 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95020F00002 | 541712 | TASK ORDER TITLE: NON-CLINICAL SAFETY OF MITRAGYNINE TO SUPPORT ITS FUTURE ORAL THERAPY FOR ANALGESIA INDICATION. POP: 09/17/2020 TO 03/16/2022. | $55K |
| Jun 21, 2024 | Department of Health and Human ServicesNIH NCI | 75N91022C00010 | 541715 | PRECLINICAL TOXICOLOGY OF LARGE MOLECULE DRUGS DEVELOPED FOR CANCER AND OTHER INDICATIONS | $375K |
| Jun 21, 2024 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95024F00002 | 541715 | IITRI - PTTP DRF BPN STUDY - TO3 | $56K |
| Jun 10, 2024 | Department of Health and Human ServicesNIH NCI | 75N91024F00002 | 541715 | TOXICOLOGY STUDIES IN MICE AND DOGS ADMINISTERED MTX-531 | $1.3M |
| Jun 3, 2024 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95020F00002 | 541712 | TASK ORDER TITLE: NON-CLINICAL SAFETY OF MITRAGYNINE TO SUPPORT ITS FUTURE ORAL THERAPY FOR ANALGESIA INDICATION. POP: 09/17/2020 TO 03/16/2022. | $79K |
| Mar 25, 2024 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95020F00001 | 541712 | NON-CLINICAL SAFETY OF PTH-1A, INVERSE AGONIST, TO SUPPORT JANSEN METAPHYSEAL CHONDRODYSPLASIA (JMC) DISEASE. POP: 09/16/2020 TO 03/15/2020. | $35K |
| Mar 14, 2024 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95024F00003 | 541715 | IITRI -DOG MTD-DRF STUDIES-TO 4 | $211K |
| Mar 12, 2024 | Department of Health and Human ServicesNIH NCI | 75N91022C00010 | 541715 | PRECLINICAL TOXICOLOGY OF LARGE MOLECULE DRUGS DEVELOPED FOR CANCER AND OTHER INDICATIONS | $301K |
| Mar 1, 2024 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95024F00001 | 541715 | IITRI - PERFORMANCE AREA 1 TO2 | $82K |
| Mar 1, 2024 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95024F00002 | 541715 | IITRI - PTTP DRF BPN STUDY - TO3 | $164K |
| Feb 20, 2024 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95020F00002 | 541712 | TASK ORDER TITLE: NON-CLINICAL SAFETY OF MITRAGYNINE TO SUPPORT ITS FUTURE ORAL THERAPY FOR ANALGESIA INDICATION. POP: 09/17/2020 TO 03/16/2022. | $9K |
| Feb 20, 2024 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95020F00001 | 541712 | NON-CLINICAL SAFETY OF PTH-1A, INVERSE AGONIST, TO SUPPORT JANSEN METAPHYSEAL CHONDRODYSPLASIA (JMC) DISEASE. POP: 09/16/2020 TO 03/15/2020. | $21K |
| Feb 2, 2024 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95020F00001 | 541712 | NON-CLINICAL SAFETY OF PTH-1A, INVERSE AGONIST, TO SUPPORT JANSEN METAPHYSEAL CHONDRODYSPLASIA (JMC) DISEASE. POP: 09/16/2020 TO 03/15/2020. | $59K |
| Jan 3, 2024 | Department of Health and Human ServicesNIH NCI | 75N91018F00005 | 541711 | IGF::OT::IGF LFA-9 (MPGES-1/5-LOX INHIBITOR): PRECLINICAL STUDIES TO SUPPORT A CLINICAL TRIAL, POP 9/17/18-9/16/2020 (UP TO 9/17/2021 IF ALL OPTIONAL TASKS EXERCISED) | $39K |
| Sep 18, 2023 | Department of Health and Human ServicesNIH NCI | 75N91023F00001 | 541714 | BASE TITLE: PREVENT PRECLINICAL PHARMACOLOGY AND TOXICOLOGY TASK ORDER TITLE: NICOTINE REDUCTION THERAPY USING THE HUMAN MONOCLONAL ANTIBODY ATI-1013 | $659K |
| Sep 14, 2023 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95020F00003 | 541712 | NON-CLINICAL SAFETY ASSESSMENT OF DRINABANT, A CANNABINOID RECEPTOR (CB-1) ANTAGONIST, FOR ACUTE CANNABINOID OVERDOSE (ACO). POP: 09/25/2020 TO 03/24/2021. | $1.4M |
| Aug 9, 2023 | Department of Health and Human ServicesNIH NCI | 75N91022C00010 | 541715 | PRECLINICAL TOXICOLOGY OF LARGE MOLECULE DRUGS DEVELOPED FOR CANCER AND OTHER INDICATIONS | $677K |
| Jun 30, 2023 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95020F00001 | 541712 | NON-CLINICAL SAFETY OF PTH-1A, INVERSE AGONIST, TO SUPPORT JANSEN METAPHYSEAL CHONDRODYSPLASIA (JMC) DISEASE. POP: 09/16/2020 TO 03/15/2020. | $202K |
| Jun 29, 2023 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95020F00002 | 541712 | TASK ORDER TITLE: NON-CLINICAL SAFETY OF MITRAGYNINE TO SUPPORT ITS FUTURE ORAL THERAPY FOR ANALGESIA INDICATION. POP: 09/17/2020 TO 03/16/2022. | $224K |
| Jun 29, 2023 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95022F00001 | 541712 | NON-CLINICAL SAFETY ASSESSMENT OF COVALENT BI-TOX TO SUPPORT NEUROPATHIC PAIN INDICATION | $22K |
| Mar 28, 2023 | Department of Health and Human ServicesNIH NCI | 75N91020F00001 | 541714 | TASK ORDER: TOPICAL RESATORVID FOR NONMELANOMA SKIN CANCER PREVENTION PERIOD OF PERFORMANCE: 09/21/2020 - 03/20/2022 | $645K |
| Mar 23, 2023 | Department of Health and Human ServicesNIH NCI | 75N91022C00010 | 541715 | PRECLINICAL TOXICOLOGY OF LARGE MOLECULE DRUGS DEVELOPED FOR CANCER AND OTHER INDICATIONS | $309K |
| Mar 2, 2023 | Department of Health and Human ServicesNIH NCI | 75N91022C00010 | 541715 | PRECLINICAL TOXICOLOGY OF LARGE MOLECULE DRUGS DEVELOPED FOR CANCER AND OTHER INDICATIONS | $471K |
| Feb 22, 2023 | Department of Health and Human ServicesNIH NCI | 75N91018F00005 | 541711 | IGF::OT::IGF LFA-9 (MPGES-1/5-LOX INHIBITOR): PRECLINICAL STUDIES TO SUPPORT A CLINICAL TRIAL, POP 9/17/18-9/16/2020 (UP TO 9/17/2021 IF ALL OPTIONAL TASKS EXERCISED) | $419K |
| Sep 23, 2022 | Department of Health and Human ServicesNIH NCI | 75N91022F00001 | 541715 | CONTRACT ORIENTATION & KICKOFF MEETING FOR R&D SERVICES UNDER "PRECLINICAL TOXICOLOGY OF SMALL MOLECULE DRUGS DEVELOPED FOR CANCER AND OTHER INDICATIONS" | $3K |
| Sep 22, 2022 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95022F00001 | 541712 | NON-CLINICAL SAFETY ASSESSMENT OF COVALENT BI-TOX TO SUPPORT NEUROPATHIC PAIN INDICATION | $744K |
| Jul 15, 2022 | Department of Health and Human ServicesNIH NCI | 75N91020F00001 | 541714 | TASK ORDER: TOPICAL RESATORVID FOR NONMELANOMA SKIN CANCER PREVENTION PERIOD OF PERFORMANCE: 09/21/2020 - 03/20/2022 | $123K |
| Jun 22, 2022 | Department of Health and Human ServicesNIH NCI | 75N91022C00010 | 541715 | PRECLINICAL TOXICOLOGY OF LARGE MOLECULE DRUGS DEVELOPED FOR CANCER AND OTHER INDICATIONS | $675K |
| May 4, 2022 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95020F00001 | 541712 | NON-CLINICAL SAFETY OF PTH-1A, INVERSE AGONIST, TO SUPPORT JANSEN METAPHYSEAL CHONDRODYSPLASIA (JMC) DISEASE. POP: 09/16/2020 TO 03/15/2020. | $698K |
Get Alerted Before Iit Research Institute's Next Recompete
Mindy monitors active contracts and flags recompetes 12 months out so you can position to compete.
Start for free